Literature DB >> 7968074

Oral contraceptive use and adenocarcinoma of cervix.

G Ursin1, R K Peters, B E Henderson, G d'Ablaing, K R Monroe, M C Pike.   

Abstract

The incidence of adenocarcinoma of the cervix in the USA more than doubled between the early 1970s and the mid 1980s among women under 35 years of age. It was suggested that this increase was due to the introduction of oral contraceptives in the early 1960s. Adenocarcinoma of the cervix diagnosed in women born after 1935 was identified between 1977 and 1991 from the Los Angeles County Cancer Surveillance Program. Data from personal interviews of 195 cases and 386 controls (matched on age, race, and neighbourhood) were analysed. Information on medical, sexual, contraceptive, and reproductive history, previous cervical smears, and sexually transmitted diseases was collected. Compared with never use, ever use of oral contraceptives was associated with twice as great a risk of adenocarcinoma of the cervix (adjusted odds ratio 2.1, 95% CI 1.1-3.8). The highest risk was observed for oral contraceptive use for more than 12 years (4.4, 1.8-10.8). No additional increased risk was found for early age at start of oral contraceptive use, use before age 20 or before first pregnancy, time since first use, time since last use, or particular formulations, once total duration of use had been accounted for.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7968074     DOI: 10.1016/s0140-6736(94)90567-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  12 in total

Review 1.  Systematic literature reviews and meta-analyses: part 6 of a series on evaluation of scientific publications.

Authors:  Meike Ressing; Maria Blettner; Stefanie J Klug
Journal:  Dtsch Arztebl Int       Date:  2009-07-03       Impact factor: 5.594

2.  Is oral contraceptive associated with genital warts?

Authors:  J D Ross
Journal:  Genitourin Med       Date:  1996-10

Review 3.  Aetiology, pathogenesis, and pathology of cervical neoplasia.

Authors:  M J Arends; C H Buckley; M Wells
Journal:  J Clin Pathol       Date:  1998-02       Impact factor: 3.411

4.  Decreasing rates of cervical cancer among American Indians and Hispanics in New Mexico (United States).

Authors:  A Chao; T M Becker; S W Jordan; R Darling; F D Gilliland; C R Key
Journal:  Cancer Causes Control       Date:  1996-03       Impact factor: 2.506

Review 5.  Hormonal contraception in adolescents: special considerations.

Authors:  Rollyn M Ornstein; Martin M Fisher
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

6.  Sexual, reproductive, and other risk factors for adenocarcinoma of the cervix: results from a population-based case-control study (California, United States)

Authors:  G Ursin; M C Pike; S Preston-Martin; G d'Ablaing; R K Peters
Journal:  Cancer Causes Control       Date:  1996-05       Impact factor: 2.506

7.  Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case-control and a case-case comparison.

Authors:  Huiyan Ma; Leslie Bernstein; Ronald K Ross; Giske Ursin
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

Review 8.  A Retrospective Study and Literature Review of Cervical Villoglandular Adenocarcinoma: A Candidate Paradigm of Silva System Pattern A.

Authors:  Yixuan Zhang; Yuxiang Wang; Yan Liu; Jing Yang; Congrong Liu
Journal:  Appl Immunohistochem Mol Morphol       Date:  2021-07-01

9.  Cervical dysplasia and cancer and the use of hormonal contraceptives in Jamaican women.

Authors:  Norma McFarlane-Anderson; Patience E Bazuaye; Maria D Jackson; Monica Smikle; Horace M Fletcher
Journal:  BMC Womens Health       Date:  2008-05-30       Impact factor: 2.809

10.  Risk factors for adenocarcinoma and squamous cell carcinoma of the cervix in women aged 20-44 years: the UK National Case-Control Study of Cervical Cancer.

Authors:  J Green; A Berrington de Gonzalez; S Sweetland; V Beral; C Chilvers; B Crossley; J Deacon; C Hermon; P Jha; D Mant; J Peto; M Pike; M P Vessey
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.